Abstracts tagged "quality of life"

Abstract Number: 0878 • ACR Convergence 2021
Investigating the Neutrophil to Lymphocyte Ratio as a Marker of SLE Disease Activity, Health-Related Quality of Life and Depression
Eleni Papachristodoulou¹, Loukas Kakoullis¹, Savvas Psarelis², Victor Hajiroussos³, Costas Christophi⁴ and Konstantinos Parperis¹, ¹University of Cyprus Medical School, Nicosia, Cyprus, ²Nicosia General Hospital/University of Cyprus Medical Schooll, Nicosia, Cyprus, ³Ygia Polyclinic Hospital, Limassol, Cyprus, ⁴Cyprus University of Technology, Limassol, Cyprus
Background/Purpose: The need for readily available markers of SLE activity has led to the evaluation of laboratory parameters, such as the neutrophil to lymphocyte ratio…
Abstract Number: 1347 • ACR Convergence 2021
Ixekizumab Efficacy in Patients with Psoriatic Arthritis Presenting with Symptoms Indicative of Axial Involvement
Atul Deodhar¹, Dafna Gladman², Rebecca Bolce³, David Sandoval³, So Young Park³, Soyi Liu-Leage⁴, Peter Nash⁵ and Denis Poddubnyy⁶, ¹Oregon Health & Science University, Portland, OR, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, Neuilly sur Seine, France, ⁵Griffith University, Brisbane, Australia, ⁶Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Many patients with psoriatic arthritis (PsA) experience back pain and stiffness indicative of axial involvement [1]. The prevalence of axial involvement varies between 25-70%…
Abstract Number: PP03 • ACR Convergence 2021
Navigating Maintenance of a Rare Autoimmune Rheumatic Disease in the Context of the COVID-19 Pandemic
Ida Hakkarinen, Greenbelt, MD
Background/Purpose: On March 13th, 2020, the President of the United States issued a proclamation declaring that the outbreak of coronavirus disease 2019 (COVID-19) was a…
Abstract Number: 0373 • ACR Convergence 2021
Self-monitoring of Disease Activity with a Smartphone App Is Feasible in Routine Clinical Management of Patients with Axial Spondyloarthritis – a Proof of Concept Study
Uta Kiltz¹, Robin Kempin¹, Jutta Richter², Anna Schlegel¹, Xenofon Baraliakos¹, Styliani Tsiami¹, Bjoern Buehring¹, David Kiefer³ and Juergen Braun¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Essen, Germany
Background/Purpose: Assessment and monitoring of disease activity and functioning is of major importance for qualified management of patients with axial spondyloarthritis (axSpA). This includes tight…
Abstract Number: 0891 • ACR Convergence 2021
Quality of Life Assessment in an Indian Inception Cohort (INSPIRE) of SLE Using Lupus QoL Questionnaire
Liza Rajasekhar¹, Dhundra Bhavani¹, Sneha Tota², Vishnupriya Vijayalekshmi³, Ranjan Gupta⁴, Chengappa Kavadichanda⁵, Vineeta Shobha⁶, VirSingh Negi⁷ and Amita Aggarwal², ¹NIMS, Hyderabad, India, ²Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, ³AIIMS, New delhi, delhi, India, ⁴AIIMS, New delhi, Ne Delhi, India, ⁵JIPMER, Pondicherry, India, ⁶Saint Johns Medical college, Bengaluru, Bengaluru, India, ⁷Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India
Background/Purpose: Lupus quality of life (Lupus QoL) questionnaire is a disease specific patient reported outcome that is available in multiple languages1. Indian SLE inception cohort…
Abstract Number: 1392 • ACR Convergence 2021
Assessment of a Patient Self-Report Frailty Tool in Patients with Polymyalgia Rheumatica
Sebastian Sattui, Deanna Jannat-Khah, Lindsay Lally, Sarah Lieber, Lisa Mandl and Robert Spiera, Hospital for Special Surgery, New York, NY
Background/Purpose: Frailty, a syndrome characterized by decreased physiologic reserve, is associated with chronic inflammation. We have shown a high prevalence of frailty in patients with…
Abstract Number: PP10 • ACR Convergence 2021
Discovering ‘I’ Through Interaction with Support Group Members: A Place of Empathy That Transcends the Limitations of Words
Noriko Okochi¹, Eiji Oishi² and Mika Ishiguro¹, ¹Rheumatic Disease and Vasculitis Support Network Japan, Tokyo, Japan, ²Rheumatic Disease and Vasculitis Support Network Japan, Yamaguchi, Japan
Background/Purpose: Since 5-year-old, I have had unexplained symptoms. At the age of 13, my whole body became inflamed. The pain was so intense that I…
Abstract Number: 0376 • ACR Convergence 2021
Impact of Patient and Disease Characteristics on Global Functioning and Health in Patients with Axial Spondyloarthritis: A Bayesian Network Analysis of Data from an Early axSpA Cohort
Imke Redeker¹, Robert Landewé², Désirée van der Heijde³, Sofia Ramiro⁴, Annelies Boonen⁵, Maxime Dougados⁶, Juergen Braun⁷ and Uta Kiltz⁷, ¹German Rheumatism Research Centre (DRFZ), Berlin, Germany, ²Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+ (MUMC+), Maastricht, Limburg, Netherlands, ⁶Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, ⁷Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Current knowledge on the health status of patients (pts.) with axial spondyloarthritis (axSpA) mainly focusses on physical function and disease activity. Using a generic…
Abstract Number: 0925 • ACR Convergence 2021
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs
Philip Mease¹, Robert McLean², Taylor Blachley², Maya Marchese², Laura Anatale-Tardiff³, Christopher Saffore⁴, Danny Quach⁵, Ana Biljan⁶ and Alexis Ogdie⁷, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³CorEvitas, Waltham, MA, ⁴AbbVie, North Chicago, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶Abbvie Inc., Chicago, IL, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Although Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity (LDA) is a common treatment target for disease control when managing AS, real-world research…
Abstract Number: 1451 • ACR Convergence 2021
Improving Health Outcomes and Social Connectedness Through Virtual Exercise Programs in Community Members with Musculoskeletal Conditions
Titilayo Ologhobo¹, Bertilia Trieu², Claudia Zurlini¹, Bonnie McGrath¹, Linda Roberts¹, Vilma Briones¹, Pamela Sanchez-Villagomez², Robyn Wiesel¹, Sandra Goldsmith¹ and Laura Robbins¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital of Special Surgery, New York
Background/Purpose: According to the 2020 American Health Ranking System, 26% of adults are physically inactive with a higher prevalence found in adults ages ≥65 years.…
Abstract Number: PP13 • ACR Convergence 2021
CreakyKitchen: How the Online Cooking Show I Started is Building Community and Encouraging Better Food Choices for Me and Others Living with Rheumatic and Chronic Disease
Chantelle Marcial, Boston, MA
Background/Purpose: At 19, I was mis-diagnosed with Lupus as it was a common condition in my family. My treatment at that time was mainly DMARDs,…
Abstract Number: 0402 • ACR Convergence 2021
What Is the Patient’s Perspective on Symptoms Experience in Limited Cutaneous Systemic Sclerosis?
Alain Lescoat¹, Susan Murphy², Yen Chen³, Nadia Vann¹, David Cella⁴ and Dinesh Khanna³, ¹Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²University of Michigan, Grosse Ile, MI, ³University of Michigan, Ann Arbor, MI, ⁴Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Limited cutaneous SSc (lcSSc) affects approximately 60-70% of SSc patients but drug development and therapeutic research has largely focused on the more severe diffuse…
Abstract Number: 0955 • ACR Convergence 2021
The Effect of Treatment with the Complement C5a Receptor Inhibitor Avacopan on Health-Related Quality of Life in ANCA-Associated Vasculitis
Vibeke Strand¹, Pirow Bekker², Huibin Yue², David R.W. Jayne³ and Peter Merkel⁴, ¹Stanford University School of Medicine, Portola Valley, CA, ²ChemoCentryx, San Carlos, CA, ³University of Cambridge, Cambridge, United Kingdom, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Avacopan, an oral C5a receptor inhibitor, was evaluated in ANCA-associated vasculitis (AAV). Efficacy and safety results were reported previously. Health-related quality of life (HRQoL)…
Abstract Number: 1591 • ACR Convergence 2021
Impact of the COVID-19 Pandemic and Lockdown on Wellbeing on Patients with Rheumatic Diseases. Results from the REUMAVID Study (Phase 1)
Marco Garrido-Cumbrera¹, Helena Marzo-Ortega², Laura Christen³, José Correa-Fernández⁴, Sergio Sanz-Gomez⁴, Pedro Plazuelo-Ramos⁵, Laurent Grange⁶, Dale Webb⁷, Shantel Irwin⁸, Clare Jacklin⁹, Souzi Makri¹⁰, Elsa Frazão Mateus¹¹, Serena Mingolla¹², Katy Antonopoulou¹³ and Victoria Navarro-Compán¹⁴, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²NIHR Leeds Biomedical Research Centre and University of Leeds, Leeds, United Kingdom, ³Novartis Pharma AG, Basel, Switzerland, ⁴Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁵Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain, ⁶French League Against Rheumatism (AFLAR), Echirolles, France, ⁷National Axial Spondyloarthritis Society (NASS), London, United Kingdom, ⁸Arthritis Action, London, United Kingdom, ⁹National Rheumatoid Arthritis Society (NRAS), London, United Kingdom, ¹⁰Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ¹¹Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, ¹²Italian National Association of People with Rheumatic and Rare Diseases (APMARR), Bari, Italy, ¹³Hellenic League Againts Rheumatism (ELEANA), Athens, Greece, ¹⁴Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain
Background/Purpose: The COVID-19 pandemic has impacted wellbeing of patients with Rheumatic and Musculoskeletal Diseases (RMDs). The aim is to assess wellbeing its associated factors in…
Abstract Number: 0560 • ACR Convergence 2021
Effectiveness, Safety, Quality of Life and Patient Satisfaction with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: Second Interim Analysis of a German Non-Interventional, Prospective, Multi-Center Study
Klaus Krüger¹, Frank Behrens², Ulrich Prothmann³, Thilo Klopsch⁴, Lisa Blindzellner⁵, Olaf Behmer⁵, Jürgen Jobst⁵, Pascal Klaus⁵, Thomas Meng⁵ and Peter-Andreas Löschmann⁵, ¹Rheumatological Practice Center, Munich, Germany, ²CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine & Pharmacology, Goethe University Hospital, Frankfurt, Germany, ³Knappschaftsklinikum Saar, Püttlingen, Germany, ⁴Rheumatological Practice, Neubrandenburg, Germany, ⁵Pfizer Pharma GmbH, Berlin, Germany
Background/Purpose: Tofacitinib is a Janus kinase inhibitor, which is orally applied and is approved for rheumatoid arthritis among other indications. ESCALATE-RA is the first prospective,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].